Treatment with HCQ vs standard therapy alone was linked to higher live birth rates and fewer obstetric complications among pregnant women with APS.

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.

The Food and Drug Administration has granted Breakthrough Therapy designation to CD388 for seasonal influenza prevention.

Patients with IPF and emphysema who received antifibrotic agents had similar outcomes to patients with IPF alone.

Results of an RCT showed that CBD 50 mg was not superior to placebo for reducing pain intensity among patients with fibromyalgia.

Eugene Declercq, Ph.D., from Boston University in Massachusetts, and colleagues conducted a retrospective cohort study to examine the association between pregnancy-associated death or severe maternal ...

The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

Patients with PsA who are treated with CTT are not at a greater risk for serious or opportunistic infections compared with standard therapy.

Adults with vs without chronic back pain have a higher prevalence of noncommunicable diseases and comorbidities.

Results of a meta-analysis showed that a history of allergies, multiorgan involvement, and decreased complement levels were linked to higher risk for IgG4-RD relapse.